Company intelligence / Profile preview
Soligenix
Princeton, New Jersey, United Statessoligenix.com ↗
- Ownership
- Public · SNGX
- Employees
- ~14
- Development stage
- Other
01
Overview
HyBryte™ completed a pivotal Phase 3 trial for early-stage CTCL with confirmatory Phase 3 ongoing; top-line results expected in late-stage trials of SGX945 for Behçet's disease and SGX302 for psoriasis. RiVax™ has shown safety/immunogenicity in two Phase 1 studies. Multiple programs have orphan drug or fast track designations.
- Therapeutic areas
- Infectious DiseasesDermatologyGastroenterologyOncologyImmunology
- Modalities
- Small moleculePeptideVaccine
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Sterling Pharma Solutions [manufacturing partnership on synthetic hypericin production]Intrexon [collaboration on melioidosis therapy]US government agencies including NIAID/DTRA/BARDA [grant funding/support]
04
Financials
- Market cap
- $7.3M
- Total revenue
- $0
- Enterprise value
- $-2.3M
Beyond the preview
Go deeper on Soligenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soligenix.